A low-key cancer discovery alliance sees Roche abandoning its earlier opposition to cell therapies.
The first human data from the Car-NK project FT596 are impressive – but not impressive enough for a company worth $9bn.
The glacial development of Fate’s anti-CD19 Car-NK therapy FT596 could yield real data at last.
PDS and Spectrum rise, while Black Diamond, Alpine, Harpoon and Macrogenics disappoint, and others ride on big pharma’s coattails.
The company is now in the clinic, claiming to have cleared one of the biggest hurdles blocking development of an NK cell therapy.
Nantkwest claims efficacy with its most advanced NK cell therapy but, as ever with Patrick Soon-Shiong companies, it’s complicated.
IGM’s snowballing share price belies some other major Ash winners, and will make Christmas unhappy for funds that had shorted the stock.
With many of the usual targets on display Fate, Celyad, Allovir and others look to maintain momentum.